Equity Analysis

Corporate News - Detailed News
Dr Reddy's completes divestment of ZEMBRACE® SYMTOUCH® and TOSYMRA™ to Upsher-Smith Laboratories
20-Jul-19   16:15 Hrs IST
Dr. Reddy's Laboratories announced the closure of the transaction with Upsher-SmithLaboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closingconditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Actof 1976 (HSR Act), as amended.

Under the agreement Dr. Reddy's sold its US and select territory rights for ZEMBRACE® SYMTOUCH®(sumatriptan injection) 3 mg and TOSYMRA™ (sumatriptan nasal spray) 10 mg, which werecommercialized through its wholly owned subsidiary, Promius Pharma, LLC

Powered by Capital Market - Live News